STML Stemline Therapeutics, Inc.

12.95
-0.3  -2.26%
Previous Close 13.25
Open 13.25
Price To book 3.59
Market Cap 231.11M
Shares 17,846,000
Volume 116,732
Short Ratio 6.77
Av. Daily Volume 178,667

SEC filingsSee all SEC filings

  1. 8-K - Current report 17512867
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981476
  3. 8-K - Current report 161980063
  4. 8-K - Current report 161850381
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161814150

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing. ASH oral presentation - December 2016.
SL-401
High Risk Myeloproliferative Neoplasms
Phase 2 enrollment to be completed 1Q 2017. BLA filing due 2H 2017.
SL-401
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer
Phase 2 preliminary data released November 2016.
SL-701
Second line glioblastoma (GBM) cancer
Phase 2 ongoing. ASH oral presentation - December 2016.
SL-401
Cancer- adult relapsed or refractory acute myeloid leukemia (AML)

Latest News

  1. Stemline Therapeutics Announces Date Change for the Company’s Presentation at the 35th Annual J.P. Morgan Healthcare Conference
  2. Biotech Movers: EnteroMedics Inc (ETRM) And Stemline Therapeutics Inc (STML)
  3. Stemline Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
  4. Why Stemline Therapeutics Inc Stock Is Climbing Today
  5. Friday’s 6 Biopharma Movers That Can’t Be Ignored
  6. STEMLINE THERAPEUTICS INC Files SEC form 8-K, Other Events
  7. Stemline shares surge on plan to get quick approval of leukemia drug
  8. Stemline Therapeutics Announces Positive FDA Meeting and Agreement on Expedited Pathway to Full Approval of SL-401 in First-Line BPDCN
  9. Stemline Therapeutics Announces Positive FDA Meeting and Agreement on Expedited Pathway to Full Approval of SL-401 in First-Line BPDCN
  10. Is Stemline Therapeutics Inc (STML) a Good Stock to Buy?
  11. Stemline Therapeutics Presents SL-401 Lead-in Results from its Ongoing Phase 2 Trial in AML in Remission with MRD and Phase 2 Trial in High-Risk Myeloproliferative Neoplasms (MPN) at ASH
  12. Stemline Therapeutics’ SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASH; High Response Rates Maintained Across All Lines
  13. Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at the 2016 ASH Meeting this Weekend
  14. Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 21st Annual Meeting of the Society of Neuro-Oncology (SNO)
  15. STEMLINE THERAPEUTICS INC Financials
  16. ETF’s with exposure to Stemline Therapeutics, Inc. : November 10, 2016
  17. Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016
  18. STEMLINE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  19. Stemline Therapeutics Reports Third Quarter 2016 Financial Results and Highlights Recent Regulatory and Clinical Progress
  20. Stemline Therapeutics Reports Third Quarter 2016 Financial Results and Highlights Recent Regulatory and Clinical Progress

SEC Filings

  1. 8-K - Current report 17512867
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981476
  3. 8-K - Current report 161980063
  4. 8-K - Current report 161850381
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161814150
  6. 8-K - Current report 161808018
  7. 8-K - Current report 161698880
  8. S-8 - Securities to be offered to employees in employee benefit plans 161692861
  9. 8-K - Current report 161674854
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 161632797